These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26122843)

  • 81. An aptamer interacting with heat shock protein 70 shows therapeutic effects and prognostic ability in serous ovarian cancer.
    Lin CN; Tsai YC; Hsu CC; Liang YL; Wu YY; Kang CY; Lin CH; Hsu PH; Lee GB; Hsu KF
    Mol Ther Nucleic Acids; 2021 Mar; 23():757-768. PubMed ID: 33614227
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers.
    Bartlett TE; Jones A; Goode EL; Fridley BL; Cunningham JM; Berns EM; Wik E; Salvesen HB; Davidson B; Trope CG; Lambrechts S; Vergote I; Widschwendter M
    PLoS One; 2015; 10(12):e0143178. PubMed ID: 26629914
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Novel Model for Comprehensive Assessment of Robust Prognostic Gene Signature in Ovarian Cancer Across Different Independent Datasets.
    Bing Z; Yao Y; Xiong J; Tian J; Guo X; Li X; Zhang J; Shi X; Zhang Y; Yang K
    Front Genet; 2019; 10():931. PubMed ID: 31681404
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro.
    Filipe A; Katopodis P; Chudasama D; Kerslake R; Jeyaneethi J; Anikin V; Silva E; Kyrou I; Randeva HS; Sisu C; Hall M; Karteris E
    J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207688
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Differential Regulation of Genes by the Glucogenic Hormone Asprosin in Ovarian Cancer.
    Kerslake R; Sisu C; Panfilov S; Hall M; Khan N; Jeyaneethi J; Randeva H; Kyrou I; Karteris E
    J Clin Med; 2022 Oct; 11(19):. PubMed ID: 36233808
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Age-related copy number variations and expression levels of F-box protein FBXL20 predict ovarian cancer prognosis.
    Zheng S; Fu Y
    Transl Oncol; 2020 Dec; 13(12):100863. PubMed ID: 32898767
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Novel Roles for Platinum and Taxane Agent Skin Testing in Risk Stratification of Chemotherapy Hypersensitivity.
    Otani IM; Castells M
    J Allergy Clin Immunol Pract; 2020 May; 8(5):1665-1667. PubMed ID: 32389278
    [No Abstract]   [Full Text] [Related]  

  • 88. Circulating Tumor Cell-Free DNA Genes as Prognostic Gene Signature for Platinum Resistant Ovarian Cancer Diagnosis.
    Gunderson CC; Radhakrishnan R; Gomathinayagam R; Husain S; Aravindan S; Moore KM; Dhanasekaran DN; Jayaraman M
    Biomark Insights; 2022; 17():11772719221088404. PubMed ID: 35370397
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Ovarian Cancer Prognostic Prediction Model Using RNA Sequencing Data.
    Jeong S; Mok L; Kim SI; Ahn T; Song YS; Park T
    Genomics Inform; 2018 Dec; 16(4):e32. PubMed ID: 30602093
    [TBL] [Abstract][Full Text] [Related]  

  • 90. MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer.
    Pal MK; Jaiswar SP; Dwivedi VN; Tripathi AK; Dwivedi A; Sankhwar P
    Cancer Biol Med; 2015 Dec; 12(4):328-41. PubMed ID: 26779370
    [TBL] [Abstract][Full Text] [Related]  

  • 91. CD73 is associated with poor prognosis in high-grade serous ovarian cancer.
    Turcotte M; Spring K; Pommey S; Chouinard G; Cousineau I; George J; Chen GM; Gendoo DM; Haibe-Kains B; Karn T; Rahimi K; Le Page C; Provencher D; Mes-Masson AM; Stagg J
    Cancer Res; 2015 Nov; 75(21):4494-503. PubMed ID: 26363007
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    Tewari KS; Eskander RN; Monk BJ
    Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.
    Nagle CM; Dixon SC; Jensen A; Kjaer SK; Modugno F; deFazio A; Fereday S; Hung J; Johnatty SE; ; Fasching PA; Beckmann MW; Lambrechts D; Vergote I; Van Nieuwenhuysen E; Lambrechts S; Risch HA; Rossing MA; Doherty JA; Wicklund KG; Chang-Claude J; Goodman MT; Ness RB; Moysich K; Heitz F; du Bois A; Harter P; Schwaab I; Matsuo K; Hosono S; Goode EL; Vierkant RA; Larson MC; Fridley BL; Høgdall C; Schildkraut JM; Weber RP; Cramer DW; Terry KL; Bandera EV; Paddock L; Rodriguez-Rodriguez L; Wentzensen N; Yang HP; Brinton LA; Lissowska J; Høgdall E; Lundvall L; Whittemore A; McGuire V; Sieh W; Rothstein J; Sutphen R; Anton-Culver H; Ziogas A; Pearce CL; Wu AH; Webb PM;
    Br J Cancer; 2015 Sep; 113(5):817-26. PubMed ID: 26151456
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer.
    Singh AK; Chandra N; Bapat SA
    Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N
    J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.
    Ataseven B; du Bois A; Reinthaller A; Traut A; Heitz F; Aust S; Prader S; Polterauer S; Harter P; Grimm C
    Gynecol Oncol; 2015 Sep; 138(3):560-5. PubMed ID: 26163893
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Quantifying mRNA in Highly Degraded Fixed Tissues by Nanostring Technology: A Comparative Study.
    Azzalini E; Di Stefano B; Canzonieri V; Venesio T; Miglio U; Marchiò C; Sapino A; Previderè C; Fattorini P; Bonin S
    Methods Protoc; 2024 May; 7(3):. PubMed ID: 38804334
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy.
    Nantasupha C; Muangmool T; Charoenkwan K
    Asian Pac J Cancer Prev; 2022 Nov; 23(11):3791-3799. PubMed ID: 36444592
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Methylation of
    Zhao Y; Xu D; Wan Y; Xi Q
    Transl Cancer Res; 2020 Apr; 9(4):2919-2930. PubMed ID: 35117648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.